ATE340593T1 - Ermittlung der auswirkung von einem clostridial toxin auf muskeln - Google Patents

Ermittlung der auswirkung von einem clostridial toxin auf muskeln

Info

Publication number
ATE340593T1
ATE340593T1 AT03721336T AT03721336T ATE340593T1 AT E340593 T1 ATE340593 T1 AT E340593T1 AT 03721336 T AT03721336 T AT 03721336T AT 03721336 T AT03721336 T AT 03721336T AT E340593 T1 ATE340593 T1 AT E340593T1
Authority
AT
Austria
Prior art keywords
clostridial toxin
muscles
determining
effects
muscle
Prior art date
Application number
AT03721336T
Other languages
English (en)
Inventor
Lisa D Hanin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28039639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE340593(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE340593T1 publication Critical patent/ATE340593T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03721336T 2002-03-14 2003-03-07 Ermittlung der auswirkung von einem clostridial toxin auf muskeln ATE340593T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/099,602 US6688311B2 (en) 2002-03-14 2002-03-14 Method for determining effect of a clostridial toxin upon a muscle

Publications (1)

Publication Number Publication Date
ATE340593T1 true ATE340593T1 (de) 2006-10-15

Family

ID=28039639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721336T ATE340593T1 (de) 2002-03-14 2003-03-07 Ermittlung der auswirkung von einem clostridial toxin auf muskeln

Country Status (10)

Country Link
US (2) US6688311B2 (de)
EP (1) EP1482986B1 (de)
JP (3) JP2005520826A (de)
KR (1) KR100963798B1 (de)
AT (1) ATE340593T1 (de)
AU (1) AU2003224657A1 (de)
CA (1) CA2478762A1 (de)
DE (1) DE60308654T2 (de)
ES (1) ES2272975T3 (de)
WO (1) WO2003077954A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
EP1634155A2 (de) * 2003-06-12 2006-03-15 Control Bionics Verfahren, system und software zur interaktiven kommunikation und analyse
US7101742B2 (en) 2003-08-12 2006-09-05 Taiwan Semiconductor Manufacturing Company, Ltd. Strained channel complementary field-effect transistors and methods of manufacture
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
BRPI0508410B8 (pt) * 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
RU2257914C1 (ru) * 2004-03-31 2005-08-10 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства Здравоохранения Российской Федерации Способ лечения паралитического косоглазия
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US8996603B2 (en) * 2004-09-16 2015-03-31 Cisco Technology, Inc. Method and apparatus for user domain based white lists
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4763347B2 (ja) * 2005-06-03 2011-08-31 ポーラ化成工業株式会社 マッサージ方法又はマッサージ料の評価方法
US20060276720A1 (en) * 2005-06-03 2006-12-07 Mcginnis William C Method of using dermatomal somatosensory evoked potentials in real-time for surgical and clinical management
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
KR102110379B1 (ko) 2005-12-01 2020-05-14 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7593769B1 (en) * 2006-02-14 2009-09-22 Iq Biolabs, Inc. Surface electromyography index
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
KR101848095B1 (ko) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
DE102008032021A1 (de) * 2008-07-07 2010-01-21 Proebstle, Thomas, Dr. Verfahren zum quantitativen Analysieren der Wirkung eines Effektors auf die mit Muskelkontraktion assoziierte Motilität der Haut
US8126542B2 (en) * 2008-12-10 2012-02-28 Somaxis, Inc. Methods for performing physiological stress tests
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
RU2458627C1 (ru) * 2011-04-05 2012-08-20 Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ количественной оценки спастичности при центральном парезе
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
US20130197397A1 (en) * 2012-01-27 2013-08-01 Revance Therapeutics, Inc. Methods and Assessment Scales for Measuring Wrinkle Severity
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
JP2019122655A (ja) * 2018-01-18 2019-07-25 パシフィックメディコ株式会社 筋電位取得装置
US11752335B1 (en) 2018-02-07 2023-09-12 Mary Kay Inc. Method for determining facial muscle responses

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689668A (en) * 1967-10-18 1972-09-05 Emile Leon Piette Method of alleviating wrinkles on skin
FR2589242B1 (fr) * 1985-10-25 1988-11-25 Oreal Procede pour examiner la surface d'un echantillon et appareil pour sa mise en oeuvre
AT391998B (de) * 1987-02-02 1990-12-27 Falko Dr Skrabal Vorrichtung zur bestimmung der konzentration zumindest einer medizinischen substanz in lebenden organismen
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
GB8806737D0 (en) * 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5211894A (en) * 1990-10-09 1993-05-18 Amway Corporation Skin replication technique
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP0758900B1 (de) 1994-05-09 2002-04-10 BINDER, William J. Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
US5595740A (en) 1994-05-16 1997-01-21 University Of Florida Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US5898545A (en) * 1997-07-01 1999-04-27 International Business Machines Corporation Head load/unload and disk airflow control apparatus
KR100544060B1 (ko) 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
WO2000024419A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
ES2320849T3 (es) 1999-04-16 2009-05-29 Marvin Schwartz Procedimiento para reducir la perdida del cabello y estimular el crecimiento del mismo.
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle

Also Published As

Publication number Publication date
US7234469B2 (en) 2007-06-26
JP2005520826A (ja) 2005-07-14
US20030178029A1 (en) 2003-09-25
JP2010106026A (ja) 2010-05-13
JP2013144711A (ja) 2013-07-25
US20040060569A1 (en) 2004-04-01
CA2478762A1 (en) 2003-09-25
EP1482986B1 (de) 2006-09-27
DE60308654T2 (de) 2007-08-23
KR20040093145A (ko) 2004-11-04
AU2003224657A1 (en) 2003-09-29
KR100963798B1 (ko) 2010-06-17
DE60308654D1 (de) 2006-11-09
WO2003077954A1 (en) 2003-09-25
EP1482986A1 (de) 2004-12-08
US6688311B2 (en) 2004-02-10
ES2272975T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
ATE340593T1 (de) Ermittlung der auswirkung von einem clostridial toxin auf muskeln
ATE476719T1 (de) Verhaltensbasierte anpassung von computersystemen
WO2006033800A3 (en) System and method of automaticallymodifying an online dating service search using compatibility feedback
TW200517923A (en) Improved portrayal of navigation objects
BR9506217A (pt) Processo para identificação de estradas manuscritas e processo para determinar se dois segmentos contínuos pertencem a entradas manuscritas separadas
ATE386970T1 (de) Zugriffs- und benutzungsmethoden für webseiten
ATE212661T1 (de) Durch enzymkatalyse erhaltene therapeutische substanzen.
DE50310711D1 (de) Verfahren, datenverarbeitungseinrichtung und computerprogrammprodukt zur datenverarbeitung
NO20040193L (no) Stabilisert kraftforsyningssystem og fremgangsmate til drift av samme, samt dataprogram
DE602007008805D1 (de) Verbindungsanpassung in Abhängigkeit von der Kontrollsignalisierung
WO2005024631A3 (en) Creating and checking runtime data types
WO2003034159A1 (en) Knowledge utilization apparatus, state space navigator used for the same, and business model using the same
AU5804100A (en) Neuronal network for computer-assisted knowledge management
NO20032944D0 (no) Styringssystem for kjemisk injisering samt fremgangsmåte for kjemisk injisering i flere brönner
ATE426858T1 (de) System und verfahren zum erkennen von bísartigem code
ATE447174T1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
SE0200949D0 (sv) Method and system for curve quality control
ATE507524T1 (de) Durchführung von prüfungen an der betriebsmittelbenutzung von computerprogrammen
CA2465155A1 (en) Recommendations for intelligent data caching
Blatner Morenean approaches: Recognizing psychodrama's many facets
ATE514245T1 (de) Verfahren und vorrichtung zur bestimmung von verwürfelungscodes für die signalübertragung
WO2005048108A3 (en) System, method, and computer program product for testing program code
FR2846252B1 (fr) Procede et dispositif de chromatographie integrant une etape de concentration
ATE363705T1 (de) Verfahren und system zum ermitteln der fortbewegungszeit einer mobilen nutzer- endeinrichtung
DE69737769D1 (de) Molekülmodell für vla-4-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties